Zimbabwe has turned down a major American healthcare agreement worth $367m (272 million pounds) over five years due to Washington's demand for confidential data.
This move came to light after a government memo dated December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the deal was "unbalanced".
A government representative later stated that the United States was seeking genetic material for scientific study and commercial gain while was unwilling to share the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged more talks to secure a deal suitable to all parties so the nation's vital HIV treatment initiative can proceed.
Wider Background
This rejection follows a comparable case in neighbouring Kenya, where a high court halted a similar deal with the US after legal challenges were raised about the safety of Kenyans' medical information.
After returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump argued its spending was "wasteful" and his administration was pursuing direct bilateral deals to enhance openness and responsibility.
Based on reports, 16 African countries have so far signed these new agreements, constituting over $18.3bn in committed funds.
Details of the Rejected Deal
The money for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration could have provided significant advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently on HIV treatment through US-supported initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to share its biological resources and data for a long time, without any corresponding assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"In essence, our nation would provide the basic resources for medical research with no assurance that the end products would be available to our people if a new pandemic emerge."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were disrupting structures previously established via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to manage potential pandemics.
"This mechanism is intended to ensure that when a nation contributes its information, the resulting advantages – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome continued dialogue with our American counterparts on how subsequent co-operation could be structured in a manner that honours the independence and dignity of both nations."
Medical Community Reaction
Medical experts said it understood the official position, but urged that negotiations must proceed since much of the nation's Aids initiatives were funded by foreign aid.
"If specific concerns arise, including those involving information security or implementation frameworks, these can frequently be addressed via detailed discussion and mutually agreed protections," it said.
This impasse emphasises the continuing tensions between accepting crucial foreign assistance and safeguarding local interests in an ever more data-driven world.